perindopril has been researched along with Coronary Artery Disease in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 31 (63.27) | 29.6817 |
| 2010's | 17 (34.69) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Boytsov, SA; Burtsev, YP; Karpov, YA; Khomitskaya, YV | 1 |
| Kotsis, VT; Liakos, CI; Papadopoulos, DP | 1 |
| Dézsi, CA | 1 |
| Krysiak, R; Okopień, B | 2 |
| Barendse, R; Battes, L; Bertrand, M; Boersma, E; Deckers, JW; Ferrari, R; Fox, K; Kardys, I; Nieboer, D; Remme, WJ; Simoons, ML; Steyerberg, EW; Takkenberg, JJ | 1 |
| de Feyter, PJ; Gijsen, FJ; Regar, E; Rodriguez-Granillo, G; Schuurbiers, JC; van der Giessen, R; van der Steen, AF; Wentzel, JJ | 1 |
| Bertrand, M; Boersma, E; Brugts, JJ; Deckers, JW; Ferrari, R; Fox, K; Oemrawsingh, RM; Remme, WJ; Simoons, ML; van der Graaf, Y; van der Leeuw, J; Visseren, FL | 1 |
| Bertrand, ME; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML | 3 |
| Akkerhuis, KM; Bertrand, ME; Boersma, E; Brugts, JJ; Danser, AH; de Maat, M; Ferrari, R; Fox, KM; Oemrawsingh, RM; Redekop, WK; Remme, WJ; Rudez, G; Simoons, ML; Van Vark, LC | 1 |
| Lanfear, DE; Luzum, JA | 1 |
| Dézsi, CA; Forster, T | 1 |
| Bertrand, M; Deckers, JW; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML | 1 |
| Bertrand, M; Blann, A; Ceconi, C; Cokkinos, D; Deckers, JW; Ferrari, R; Fox, KM; Kluft, C; Parrinello, G; Remme, WJ; Simoons, ML | 1 |
| Camici, PG | 1 |
| Ventura, HO; Verma, A | 1 |
| Ferrari, R | 1 |
| Bertrand, M; Boersma, E; Brugts, JJ; Danser, AH; de Maat, MP; Ferrari, R; Fox, K; Remme, W; Simoons, ML; Uitterlinden, AG; van Duijn, C; Witteman, JC | 1 |
| Ferrari, R; Fox, K | 1 |
| Danchin, N | 1 |
| Gherli, T; Montanari, A; Passera, M; Pattoneri, P; Pelà, G; Reverberi, C; Tirabassi, G | 1 |
| Bruining, N; de Feijter, PJ; de Winter, S; Hamers, R; Heller, I; Rodriguez-Granillo, GA; Roelandt, JR; van Domburg, RT | 1 |
| Bertrand, ME; Deckers, JW; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML | 3 |
| Bertrand, M; Boersma, E; Brugts, JJ; Ceconi, C; Chalmers, J; Danser, AH; de Maat, MP; Ferrari, R; Fox, K; Isaacs, A; MacMahon, S; Ninomiya, T; Remme, W; Simoons, ML; Uitterlinden, AG; van Duijn, CM; Witteman, JC | 1 |
| Ceconi, C; Ferrari, R; Guardigli, G | 1 |
| Boersma, E; Brugts, JJ; Simoons, ML | 1 |
| Akdağ, S; Gumrukcuoglu, HA; Gunes, A; Gunes, Y; Guntekin, U; Sahin, M; Sezen, Y; Simsek, H; Tuncer, M | 1 |
| Mourad, JJ | 1 |
| Legrand, V; Scheen, AJ | 1 |
| Solignac, M | 1 |
| Karpov, IuA | 1 |
| Bertrand, ME; Daly, CA; Ferrari, R; Fox, KM; Remme, WJ; Simoons, ML | 1 |
| Leiter, LA; Lonn, EM; Strauss, MH; Verma, S | 1 |
| Campo, G; Ceconi, C; Ferrari, R; Gardini, E; Notarstefano, P; Pasanisi, G | 1 |
| Arora, RR; Shah, AD | 1 |
| Curran, MP; McCormack, PL; Simpson, D | 1 |
| Bertrand, M; Boersma, E; Briggs, A; Deckers, JW; Ferrari, R; Fox, K; Goedhart, DM; Remme, WJ; Simoons, ML | 1 |
| Abe, Y; Hirosaka, A; Hisa, S; Igarashi, M; Kijima, M; Komatsu, N; Maehara, K; Maruyama, Y; Mitsugi, M; Ohwada, T; Tsuda, T; Ujiie, Y; Yaoita, H | 1 |
| Brady, AJ | 1 |
| Bertrand, M; Daly, CA; Ferrari, R; Fox, KM; Hildebrandt, P; Remme, W; Simoons, M | 1 |
| Bertrand, M; Bruining, N; De Feyter, PJ; de Winter, S; Deckers, JW; Ferrari, R; Fox, KM; Garcia-Garcia, HM; Ligthart, JM; Remme, W; Rodriguez-Granillo, GA; Simoons, ML; Vos, J | 1 |
| Bertrand, M; Bots, ML; Ferrari, R; Fox, KM; Grobbee, DE; Lüscher, TF; Remme, WJ; Simoons, ML | 1 |
| Bruining, N; de Feyter, PJ; de Winter, S; García-García, HM; Ligthart, JM; Rodriguez-Granillo, GA; Valgimigli, M | 1 |
| Bertrand, M; Boersma, E; Brugts, JJ; Chonchol, M; Deckers, JW; Ferrari, R; Fox, K; Remme, WJ; Simoons, ML | 1 |
12 review(s) available for perindopril and Coronary Artery Disease
| Article | Year |
|---|---|
From microcirculation to cardiac event: protection with Preterax.
Topics: Antihypertensive Agents; Cardiotonic Agents; Coronary Artery Disease; Drug Combinations; Humans; Hypertension, Renal; Indapamide; Microcirculation; Perindopril | 2008 |
Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Artery Disease; Drug Combinations; Female; Humans; Hypertension; Male; Perindopril; Practice Guidelines as Topic | 2008 |
Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Topics: Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Biomarkers; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Nitric Oxide Synthase; Perindopril; von Willebrand Factor | 2009 |
Should angiotensin-converting enzyme inhibitors be used in all patients with coronary artery disease or restricted to those with a history of myocardial infarction or myocardial revascularization?
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Humans; Myocardial Infarction; Myocardial Revascularization; Patient Selection; Perindopril; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome | 2009 |
Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Topics: Acute Coronary Syndrome; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Atherosclerosis; Bradykinin; Cardiotonic Agents; Coronary Artery Disease; Disease Progression; Endothelial Cells; Endothelium, Vascular; Heart Failure; Humans; Hypertension; Peptidyl-Dipeptidase A; Perindopril; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Secondary Prevention; Stem Cells | 2010 |
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Haplotypes; Humans; Perindopril; Pharmacogenetics; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
Which patients benefit the most from the perindopril/amlodipine combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Artery Disease; Humans; Hypertension; Perindopril | 2011 |
[Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Humans; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cerebrovascular Disorders; Coronary Artery Disease; Heart Failure; Humans; Hypertension; Perindopril; Renin-Angiotensin System | 2005 |
Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Coronary Artery Disease; Heart Failure; Humans; Perindopril; Prodrugs; Risk; Treatment Outcome | 2006 |
Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Humans; Hypertension; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Heart Arrest; Heart Failure; Humans; Male; Myocardial Infarction; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Rate | 2007 |
23 trial(s) available for perindopril and Coronary Artery Disease
| Article | Year |
|---|---|
Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Cells, Cultured; Chi-Square Distribution; Coronary Artery Disease; Cytokines; Enalapril; Female; Humans; Inflammation Mediators; Insulin Resistance; Lipids; Male; Middle Aged; Monocytes; Perindopril; Poland; Time Factors; Treatment Outcome | 2012 |
Development and validation of a cardiovascular risk assessment model in patients with established coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Calibration; Cardiovascular Diseases; Chi-Square Distribution; Coronary Artery Disease; Endpoint Determination; Female; Humans; Male; Middle Aged; Perindopril; Probability; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis | 2013 |
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Decision-Making; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Perindopril; Precision Medicine; Time Factors; Treatment Outcome | 2015 |
Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Europe; Female; Hospitalization; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Patient Acuity; Perindopril; Survival Analysis; Treatment Outcome | 2015 |
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Cost-Benefit Analysis; Decision Support Techniques; Double-Blind Method; Drug Costs; Female; Genotype; Heart Arrest; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Patient Selection; Perindopril; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Proportional Hazards Models; Receptor, Angiotensin, Type 1; Receptor, Bradykinin B1; Resuscitation; Risk Assessment; Risk Factors; Treatment Outcome | 2016 |
Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiotonic Agents; Coronary Artery Disease; Drug Combinations; Drug Monitoring; Exercise Tolerance; Female; Heart Rate; Humans; Hungary; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies; Risk Factors; Treatment Outcome | 2016 |
ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Europe; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Inflammation; Inflammation Mediators; Kaplan-Meier Estimate; Perindopril; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2009 |
Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Perindopril; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome | 2009 |
Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Echocardiography, Doppler, Pulsed; Female; Heart Ventricles; Humans; Male; Middle Aged; Perindopril; Stroke Volume; Ventricular Function, Left | 2009 |
Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcinosis; Coronary Artery Disease; Double-Blind Method; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Perindopril; Predictive Value of Tests; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Coronary Artery Disease; Drug Synergism; Drug Therapy, Combination; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Perindopril; Proportional Hazards Models | 2010 |
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Female; Gene Frequency; Genotype; Heart Arrest; Humans; Kallikrein-Kinin System; Male; Middle Aged; Myocardial Infarction; Perindopril; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Receptor, Bradykinin B1; Renin-Angiotensin System | 2010 |
Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Case-Control Studies; Coronary Artery Disease; Cytokines; Double-Blind Method; Enalapril; Female; Humans; Insulin Resistance; Lipids; Lymphocytes; Male; Middle Aged; Perindopril; Phytohemagglutinins; Prospective Studies; Time Factors | 2011 |
PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Biomarkers; Cells, Cultured; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Europe; Female; Humans; Inflammation; Male; Neurotransmitter Agents; Perindopril; Risk Factors; Thrombosis; Umbilical Veins | 2003 |
[Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Female; Heart Arrest; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Placebos; Risk Factors; Treatment Outcome | 2003 |
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Death, Sudden, Cardiac; Diabetic Angiopathies; Double-Blind Method; Female; Heart Arrest; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Prospective Studies | 2005 |
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Perindopril; Risk Factors; Treatment Outcome | 2006 |
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Perindopril; Platelet Aggregation Inhibitors; Quinapril; Stents; Tetrahydroisoquinolines; Tetrazoles | 2006 |
Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus; Europe; Female; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Obesity; Perindopril; Prognosis; Risk Assessment | 2007 |
Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study).
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Angiography; Coronary Artery Disease; Disease Progression; Endosonography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Perindopril; Prospective Studies | 2007 |
ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Brachial Artery; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Ischemia; Perindopril; Treatment Outcome; Ultrasonography; Vasodilation | 2007 |
Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Observer Variation; Perindopril; Regression Analysis; Treatment Outcome; Ultrasonography, Interventional; Ventricular Remodeling | 2007 |
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Perindopril; Renal Insufficiency; Severity of Illness Index; Treatment Outcome; Ventricular Function, Left | 2007 |
14 other study(ies) available for perindopril and Coronary Artery Disease
| Article | Year |
|---|---|
Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Coronary Artery Disease; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Perindopril; Russia; Treatment Outcome | 2021 |
Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Drug Combinations; Drug Tolerance; Female; Greece; Humans; Hypertension; Male; Perindopril; Prospective Studies | 2017 |
Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.
Topics: Amlodipine; Atorvastatin; Blood Pressure; Coronary Artery Disease; Drug Combinations; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Perindopril; Risk Factors | 2018 |
Positive remodeling at 3 year follow up is associated with plaque-free coronary wall segment at baseline: a serial IVUS study.
Topics: Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Perindopril; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Risk Factors; Ultrasonography, Interventional | 2014 |
Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement?
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Perindopril; Pharmacogenetics | 2016 |
Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Perindopril; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Cardiovascular outcomes and angiotensin converting enzyme inhibitors: beyond blood pressure control. Editorial to: "Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Coronary Artery Disease; Humans; Perindopril; Treatment Outcome | 2009 |
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Perindopril; Pharmacogenetics; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Research Design | 2009 |
The effects of perindopril on QT duration and dispersion in patients with coronary slow flow.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Echocardiography; Electrocardiography; Female; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Perindopril; Time Factors; Treatment Outcome; Turkey; Ventricular Function, Left | 2011 |
[Towards the optimal management in 2004 of patients with stable coronary artery disease].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Artery Disease; Europe; Humans; Myocardial Revascularization; Perindopril; Prognosis; Treatment Outcome; Ventricular Remodeling | 2004 |
Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Coronary Artery Disease; Diabetic Angiopathies; Humans; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Perindopril | 2005 |
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Humans; Middle Aged; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Female; Heart Arrest; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Perindopril; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2007 |
Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Disease; Female; Heart Diseases; Humans; Male; Middle Aged; Myocardial Revascularization; Perindopril; Risk Factors | 2007 |